Antimicrobial resistance (AMR) is increasingly recognized as a dynamic biological phenomenon in which bacterial and other microbial pathogens adapt to the selective pressures imposed by antimicrobial agents including antibiotics, antifungal agents and antivirals. Although resistance may arise through spontaneous genetic changes, many clinically important resistance traits are acquired from external sources and subsequently maintained within microbial populations. The acquisition of resistance therefore represents more than a simple change in susceptibility; it reflects the capacity of microorganisms to capture, incorporate, express, and disseminate genetic information that can alter essential cellular processes or neutralize antimicrobial activity.
Microorganisms possess several highly effective routes for acquiring resistance-associated genetic determinants. In bacteria, horizontal gene transfer provides a major pathway through which advantageous traits can move between genetically distinct cells. Transformation permits competent bacteria to take up free DNA from their surroundings and, under appropriate conditions, incorporate functional sequences into their genomes. Conjugation provides another important route, involving direct cell-to-cell transfer of mobile genetic elements such as plasmids, which frequently carry multiple antimicrobial-resistance genes. Transduction, mediated by bacteriophages, can additionally transport bacterial DNA between cells and facilitate the movement of resistance determinants across susceptible populations. These processes can operate independently or interact with one another, creating complex networks through which resistance traits become established and disseminated.
The genetic mobility underlying resistance acquisition is further enhanced by specialized DNA elements, including plasmids, transposons, insertion sequences, integrons, and gene cassettes. Such elements can capture, rearrange, mobilize, and express resistance genes, sometimes allowing microorganisms to acquire resistance to several antimicrobial classes simultaneously. Integrons are particularly significant because of their ability to collect gene cassettes and assemble combinations of functional determinants, while transposable elements can facilitate movement of resistance genes between chromosomes and plasmids. The genetic architecture of resistance is often highly flexible rather than fixed, enabling pathogens to respond rapidly to changing antimicrobial environments.
Acquired resistance may ultimately arise through diverse molecular outcomes, including enzymatic destruction or modification of antimicrobial compounds, alteration of drug targets, reduction of intracellular drug accumulation, and development of alternative metabolic pathways. The ecological context is equally important because antimicrobial exposure creates selective conditions that favor organisms carrying advantageous resistance determinants. Once acquired, these determinants may persist through clonal expansion, continued horizontal transfer, or co-selection with other beneficial traits. Thus, resistance acquisition should be viewed as an interconnected process involving genetic mobility, molecular adaptation, selection, and microbial population dynamics. Examining these specific mechanisms provides a foundation for understanding how resistant pathogens emerge, diversify, and disseminate, while also identifying biological points at which strategies for surveillance, prevention, and antimicrobial-resistance control may be developed.
Specific mechanisms of acquiring resistance by microbial pathogens
The effectiveness of an antimicrobial agent depends on a coordinated sequence of events that begins with its delivery to the site of infection and culminates in successful interaction with an essential microbial component. After reaching the infected tissue, the antimicrobial must remain sufficiently stable, penetrate the relevant cellular barriers, attain an effective concentration, and reach its functional target. Depending on the compound, metabolic activation may also be required before antimicrobial activity can occur. At the microbial level, the drug must subsequently recognize and bind to its intended target with adequate affinity and persistence to interfere with a vital cellular process. Resistance can therefore arise whenever a microorganism acquires a characteristic that interrupts, weakens, or circumvents any of these stages.
In bacteria, the first line of interference may occur before the antimicrobial reaches its intracellular destination. Changes in the composition or architecture of the cell envelope can restrict drug penetration, while alterations in membrane channels may reduce the entry of compounds that normally depend on these pathways. Once an antimicrobial has entered the cell, bacterial transport systems can actively expel it through membrane-associated efflux pumps, preventing the intracellular concentration from reaching a bactericidal or bacteriostatic level. Other organisms may produce enzymes capable of chemically modifying or destroying antimicrobial molecules, thereby rendering them incapable of interacting effectively with their targets.
Resistance may also develop at the point of antimicrobial-target interaction. Genetic alterations can modify the structure of target molecules so that the drug binds less efficiently while the target continues to perform its essential physiological function. In other circumstances, bacteria can protect the target from antimicrobial interference or increase the production of the target, effectively reducing the impact of the drug. Such adaptations illustrate that resistance does not necessarily require complete elimination of drug activity; even a sufficient reduction in drug-target affinity or accessibility can permit bacterial survival.
A further route involves metabolic reorganization. When an antimicrobial blocks a particular biochemical reaction, bacteria may acquire alternative enzymes or metabolic routes that restore the affected cellular function. This bypass mechanism allows the organism to continue essential physiological processes despite continued presence of the antimicrobial. Similarly, mutations may alter regulatory systems, metabolic pathways, membrane structures, or cellular stress responses in ways that increase survival during antimicrobial exposure.
The genetic basis of these adaptations can be either intrinsic to the bacterial chromosome or acquired from external genetic sources. Mutational events can generate new resistance phenotypes, while horizontal gene transfer can introduce already-established resistance determinants into previously susceptible organisms. Transformation allows competent bacteria to incorporate extracellular DNA; conjugation facilitates direct transfer of genetic material, commonly through plasmids; and transduction enables bacteriophages to transport bacterial DNA between cells. Mobile elements such as plasmids, transposons, insertion sequences, integrons, and gene cassettes can further rearrange and disseminate resistance determinants, allowing several resistance traits to become associated within the same bacterial lineage.
In addition, bacterial growth within biofilms can produce a protected physiological state in which antimicrobial penetration, metabolic activity, and cellular responsiveness differ substantially from those of free-living cells. This environment can promote persistence and provide opportunities for genetic exchange, although biofilm-associated tolerance should be distinguished from genetically encoded resistance. These processes demonstrate that antimicrobial resistance can be established through changes affecting drug entry, drug elimination, drug modification, target interaction, cellular metabolism, genetic composition, and microbial community structure.
The major mechanisms through which microbes can acquire resistance can therefore be categorized as follows:
- Enzymatic destruction or modification of antimicrobial agents
- Reduced permeability and restricted antimicrobial uptake
- Active antimicrobial efflux
- Modification of antimicrobial target sites
- Protection or replacement of altered targets
- Metabolic pathway modification and bypass
- Acquisition of resistance determinants through transformation
- Acquisition of resistance determinants through conjugation
- Phage-mediated acquisition through transduction
- Mutation and chromosomal adaptation
- Mobilization of resistance genes by plasmids, transposons, and integrons
- Biofilm-associated persistence and antimicrobial tolerance
Antibiotic resistance by influx-efflux systems
The balance between antimicrobial entry and removal is a critical determinant of the concentration of an antibiotic that ultimately reaches its intracellular target. Bacteria can exploit this balance to withstand antimicrobial exposure by restricting drug influx, modifying membrane permeability, and enhancing the outward transport of compounds that threaten cellular viability. This resistance strategy is collectively associated with influx–efflux processes, although the two components should be distinguished: influx concerns the movement of antimicrobial molecules into the bacterial cell, whereas efflux involves their active export after entry. Resistance becomes particularly pronounced when reduced uptake is coupled with increased efflux, producing intracellular drug concentrations that remain below the level required for effective inhibition or killing.
In Gram-negative bacteria, antimicrobial entry is strongly influenced by the architecture of the cell envelope. The outer membrane forms an additional permeability barrier and contains porin proteins through which many hydrophilic antibiotics and other small molecules gain access to the periplasmic space. Alterations in the number, structure, selectivity, or expression of these porins can consequently reduce antimicrobial penetration. Some bacteria may downregulate particular porins, replace them with less permeable channels, or modify channel properties, thereby limiting the amount of drug that reaches the inner membrane and cytoplasmic compartments. This reduction in influx can work synergistically with other resistance mechanisms, particularly when the antimicrobial already has a relatively narrow intracellular concentration range for effective activity.
Efflux represents a more active form of resistance. Bacterial efflux pumps are membrane-associated transport systems capable of recognizing and exporting structurally diverse compounds, including antibiotics, antiseptics, dyes, detergents, and toxic metabolites. Rather than allowing the antimicrobial to accumulate inside the cell, these transporters continuously remove the compound and thereby reduce its availability at the pharmacological target. When efflux activity is sufficiently high, the intracellular concentration may remain below the threshold necessary to interfere with essential cellular processes. Increased resistance can therefore result from overexpression of existing efflux systems, changes in their regulatory networks, or acquisition of additional efflux-associated determinants.
Several major transporter families contribute to bacterial efflux, including the resistance-nodulation-division (RND), major facilitator superfamily (MFS), small multidrug resistance (SMR), multidrug and toxic compound extrusion (MATE), and ATP-binding cassette (ABC) systems. Their energy requirements and substrate preferences differ, but their collective effect is the same: decreasing the intracellular burden of antimicrobial compounds. RND systems are particularly important in many Gram-negative organisms because some function as multicomponent complexes that can transport antibiotics directly from the cell envelope or cytoplasm to the external environment. In organisms such as Escherichia coli, these systems have been extensively investigated because of their broad substrate range and contribution to multidrug resistance.
The relationship between influx and efflux is especially important because resistance does not necessarily require complete exclusion of an antibiotic. Even a modest reduction in uptake, when accompanied by accelerated extrusion, can substantially alter the drug concentration experienced by the bacterial target. Efflux activity may produce cross-resistance because a single transporter can recognize several unrelated antimicrobial classes. This broad specificity enables bacteria with highly active efflux systems to withstand multiple agents simultaneously, particularly when additional mechanisms such as target modification or enzymatic drug inactivation are present.
Influx-efflux resistance reflects a dynamic alteration of antimicrobial movement across the bacterial envelope. Reduced entry limits the quantity of drug available internally, while enhanced export removes molecules that have successfully penetrated the cell. Together, these processes can maintain intracellular antimicrobial concentrations below therapeutic effectiveness and provide bacteria with a powerful means of surviving antimicrobial exposure.
Antibiotic resistance by chemical alteration of antibiotics in vivo
Chemical alteration of antibiotics represents an important resistance strategy in which bacterial pathogens modify the molecular structure of an antimicrobial compound before it can effectively reach or act upon its intended cellular target. The therapeutic activity of an antibiotic depends not only on its ability to reach the site of infection but also on the preservation of specific chemical features required for target recognition and biological activity. When bacteria enzymatically modify, cleave, reduce, oxidize, or otherwise transform these critical structural components, the resulting drug molecule may possess greatly diminished or completely abolished antimicrobial activity. The pathogen consequently survives exposure to an antibiotic concentration that would ordinarily be sufficient to inhibit its growth or cause cellular death.
This mechanism is particularly significant because antimicrobial activity is often dependent on precise molecular interactions between the drug and its target. Even relatively small chemical modifications can alter the charge, configuration, affinity, or reactivity of an antibiotic and thereby prevent effective target engagement. Bacteria have evolved a range of enzymes capable of producing such modifications. These enzymes may be constitutively expressed or induced following antimicrobial exposure, allowing the organism to chemically neutralize the compound as part of its adaptive response. In some cases, the modified antibiotic may no longer bind efficiently to its target; in others, its ability to penetrate the bacterial cell or participate in the biochemical reaction responsible for antimicrobial activity may be substantially reduced.
A related phenomenon occurs with antimicrobial prodrugs, which require conversion into an active form within the microbial cell. Their activity depends on specific bacterial enzymes that transform the administered compound into a reactive metabolite capable of damaging essential cellular components. Genetic alterations affecting the enzymes responsible for this activation can prevent formation of the active antimicrobial species. Nitrofurantoin provides a notable example. Its antibacterial activity depends on enzymatic reduction of the nitro group by bacterial nitroreductases, generating reactive intermediates that damage microbial DNA and other cellular constituents. Mutations affecting relevant nitroreductase systems can therefore reduce drug activation and contribute to nitrofurantoin resistance, particularly in organisms exposed to the drug over time.
Chemical inactivation is also prominent among β-lactam antibiotics. Bacteria may produce β-lactamases, enzymes that hydrolyze the characteristic β-lactam ring required for the activity of penicillins, cephalosporins, and related compounds. Once this structural feature is disrupted, the antibiotic loses its ability to effectively inhibit penicillin-binding proteins involved in bacterial cell-wall synthesis. The extent of resistance depends partly on the type, quantity, and substrate range of the enzyme produced, with some β-lactamases capable of hydrolyzing a broad spectrum of β-lactam compounds.
Chemical alteration can neutralize antimicrobial agents through enzymatic modification or destruction, disruption of prodrug activation, and transformation of essential functional groups. This mechanism effectively converts an active therapeutic compound into a biologically weakened or inactive form before it can achieve its intended antibacterial effect.
Antibiotic resistance due to target Alterations
Antibiotic resistance can arise when bacteria modify the cellular structures that antimicrobial agents are designed to recognize and attack. For an antibiotic to produce its intended effect, it must interact with a particular molecular target with sufficient specificity and affinity. These targets may be enzymes, structural proteins, ribosomal components, nucleic acids, or other essential cellular constituents. When changes occur in the structure, abundance, accessibility, or functional characteristics of such targets, the antimicrobial may no longer bind effectively or may become incapable of disrupting the physiological process required for bacterial survival. Target alteration therefore represents an important mechanism through which bacteria can withstand antibiotic exposure without necessarily destroying or removing the antibiotic molecule itself.
Target modification is frequently associated with genetic changes that alter the amino-acid sequence or structural configuration of the affected cellular component. Even a relatively small alteration at the antibiotic-binding region may substantially reduce drug affinity while preserving enough of the target’s normal biological function for the organism to remain viable. In some circumstances, bacteria may also acquire genes encoding alternative forms of target proteins that perform the same physiological role but possess limited susceptibility to the antibiotic. The resulting phenotype allows the microorganism to continue essential cellular processes despite the presence of an otherwise active antimicrobial compound.
A well-established example involves the penicillin-binding proteins (PBPs), which serve as important targets for β-lactam antibiotics. PBPs are membrane-associated enzymes involved in the final stages of bacterial cell-wall construction, particularly the transpeptidation reactions responsible for strengthening the peptidoglycan network. During cell-wall synthesis, these enzymes facilitate cross-linking between peptide components associated with the glycan strands of peptidoglycan. This cross-linking provides mechanical strength and structural stability to the bacterial cell envelope.
β-lactam antibiotics, including penicillins, normally exploit this process by binding to susceptible PBPs and interfering with their enzymatic activity. Inhibition of transpeptidation weakens peptidoglycan assembly and compromises the integrity of the bacterial cell wall, ultimately contributing to cell lysis and death, particularly in actively dividing bacteria. However, structural changes in PBPs can diminish their interaction with β-lactam molecules. The altered protein may retain sufficient catalytic activity to support cell-wall synthesis while displaying substantially reduced affinity for the antibiotic. The drug is unable to inhibit peptidoglycan assembly effectively at clinically achievable concentrations.
Target alteration is not restricted to PBPs or β-lactam resistance. Changes in ribosomal targets can reduce susceptibility to antibiotics that interfere with protein synthesis, while modifications of enzymes involved in DNA replication or transcription can impair the activity of drugs directed against nucleic-acid metabolism. Such alterations may emerge through spontaneous mutation or may be introduced through horizontally acquired genetic determinants. Thus, modification of antibiotic targets provides bacteria with a means of preserving essential cellular functions while reducing the vulnerability of those functions to antimicrobial intervention.
Antibiotic resistance due to loss of drug entry points (porin channels)
Porins are integral outer-membrane proteins that form water-filled channels through which selected small molecules move across the outer membrane of Gram-negative bacteria. By creating controlled pathways for the movement of nutrients, ions, metabolites, and antimicrobial compounds, these proteins contribute substantially to the permeability characteristics of the bacterial envelope. Their biological significance therefore extends beyond nutrient acquisition, as the number, structure, distribution, and functional properties of porins can determine how readily an antimicrobial compound gains access to its intracellular site of action. When these entry pathways are diminished or disrupted, the concentration of an antimicrobial reaching its target may fall below the level required for effective inhibition or killing.
The outer membrane of Gram-negative bacteria represents a particularly important permeability barrier because it restricts the passage of many potentially harmful substances before they reach the cytoplasmic membrane or intracellular components. Porin channels provide selective routes through this barrier, with individual porins differing in channel size, charge characteristics, and substrate preference. Antibiotics that depend substantially on these pathways can be strongly affected by changes in porin expression or structure. Several hydrophilic antimicrobial agents, particularly members of the β-lactam and fluoroquinolone classes, utilize porin-mediated pathways to cross the outer membrane. Tetracyclines and chloramphenicol may also be influenced by alterations in outer-membrane permeability, although their movement across the bacterial envelope involves additional factors.
Resistance associated with porins commonly develops through genetic or regulatory changes that reduce the abundance or functionality of these channels. Mutations in porin-encoding genes may produce structurally altered channels with narrower openings, modified charge properties, or impaired permeability. Alternatively, bacteria may decrease porin synthesis through changes in transcriptional regulation, environmental responses, or global regulatory networks. In some cases, a particular porin may be completely lost and replaced by another channel with substantially lower permeability to a specific antimicrobial. The resulting reduction in drug influx limits the intracellular exposure of the bacterium and may prevent the antimicrobial from achieving its pharmacologically effective concentration.
Porin-mediated resistance can become particularly consequential when reduced drug entry occurs alongside other resistance mechanisms. For example, diminished uptake may act synergistically with enzymatic drug degradation or modification and active efflux systems, producing a substantial decline in intracellular antimicrobial accumulation. This combined effect is especially relevant in organisms such as Pseudomonas aeruginosa, Klebsiella species, and Escherichia coli, where changes in outer-membrane permeability can contribute to clinically significant resistance phenotypes.
The relationship between porins and antimicrobial susceptibility is therefore determined not simply by whether a channel is present, but by its expression level, structural integrity, substrate selectivity, and interaction with other components of the bacterial envelope. Alteration of these entry routes effectively changes the permeability landscape of the cell, allowing bacteria to withstand antimicrobial exposure by restricting access to vulnerable intracellular targets.
Antibiotic resistance due to non-heritable states of bacteria
Bacteria can survive antimicrobial exposure not only through genetically encoded resistance determinants but also by entering temporary physiological states that reduce their susceptibility to antibiotic-mediated killing. These states do not necessarily involve permanent alterations in the bacterial genome and are therefore fundamentally different from resistance acquired through plasmids, transposons, integrons, or chromosomal mutations. Instead, they represent reversible adaptations in cellular physiology, growth rate, metabolism, organization, or behaviour that enable bacterial populations to withstand otherwise effective antimicrobial concentrations. Once the environmental pressure is removed, cells may return to their normal physiological condition and regain their original susceptibility.
Non-heritable antibiotic tolerance is particularly important because conventional antimicrobial therapy generally targets actively functioning cellular processes. Antibiotics directed against cell-wall synthesis, protein production, DNA replication, or other essential pathways are often most effective against metabolically active and dividing cells. Bacteria that temporarily reduce their metabolic activity or enter specialized community-associated states can consequently become much less vulnerable to antimicrobial killing without possessing a permanent resistance gene. Such survival may provide a reservoir from which bacterial populations can recover after antimicrobial treatment has ceased.
One important example is the persister state, in which a small subpopulation of bacterial cells enters a dormant or markedly slow-growing condition. Persister cells are not genetically resistant in the conventional sense; rather, their reduced physiological activity makes them poor targets for antibiotics whose action depends on active cellular processes. These cells can remain viable during antimicrobial exposure and subsequently resume growth when favourable conditions return. Persistence is therefore closely associated with recurrent or prolonged infections and can complicate the complete eradication of bacterial populations.
Another important state is the biofilm phenotype. Biofilms are structured microbial communities attached to living or non-living surfaces and enclosed within a self-produced extracellular polymeric matrix. The matrix contains polysaccharides, proteins, extracellular DNA, lipids, and other components that contribute to cellular adhesion and community stability. Within a biofilm, antimicrobial penetration may be reduced, while altered metabolic activity and local chemical conditions can further decrease susceptibility. Cell-to-cell communication through quorum sensing can coordinate collective behaviours, including biofilm development, metabolic adaptation, and production of extracellular materials. Biofilms may therefore provide bacteria with a communal environment that favours persistence under antimicrobial stress. Their formation on catheters, implants, respiratory devices, wounds, and other surfaces is particularly relevant to persistent infections.
Swarming represents another transient bacterial lifestyle associated with collective movement across moist or semi-solid surfaces. Species such as Proteus can undergo marked physiological differentiation during swarming, producing elongated, highly motile cells that migrate cooperatively. This multicellular organization can alter growth patterns, cellular physiology, and interaction with antimicrobial compounds, thereby contributing to temporary tolerance under particular environmental conditions.
Non-heritable antibiotic tolerance encompasses reversible physiological adaptations rather than stable genetic resistance. The principal states include persistence, biofilm formation, and swarming, each of which can provide bacteria with a temporary survival advantage during antimicrobial exposure.
Phage-mediated acquisition through transduction
Transduction is a form of horizontal gene transfer in which bacteriophages act as biological carriers of genetic material between bacterial cells. During infection, a bacteriophage replicates within a bacterial host and, during the assembly of new viral particles, bacterial DNA may occasionally become incorporated into a phage particle. When such a particle subsequently infects another bacterium, the transferred DNA can enter the recipient cell and, if compatible with the recipient’s genetic machinery, become incorporated into its chromosome or persist as functional genetic material. When the transferred DNA contains an antimicrobial-resistance determinant, the recipient may acquire a new resistant phenotype.
Two broad forms of transduction are recognized: generalized transduction, in which fragments from different regions of the bacterial chromosome can be transferred because of accidental packaging of host DNA, and specialized transduction, in which particular bacterial genes located near a prophage integration site are preferentially mobilized following inaccurate excision. This mechanism enables resistance-associated genes to move between bacterial cells without requiring direct cell-to-cell contact. Transduction can consequently contribute to the spread of resistance within bacterial populations, particularly where susceptible and resistant strains coexist with compatible bacteriophages. The process also demonstrates how bacteriophages can influence bacterial evolution by serving as vectors for genetic exchange.
Mutation and chromosomal adaptation
Spontaneous or environmentally selected mutations in bacterial DNA can generate changes that reduce susceptibility to antimicrobial agents. These alterations may arise from replication errors, DNA damage, or defects in cellular repair processes and can subsequently become enriched when antimicrobial exposure favours cells carrying advantageous variants. Importantly, antibiotic exposure does not necessarily create a specific resistance mutation on demand; rather, it imposes a selective environment in which pre-existing or newly arising variants with greater survival capacity are preferentially retained.
Chromosomal mutations can affect several components of antimicrobial activity. Alterations in genes encoding drug targets may reduce the affinity between an antimicrobial compound and its cellular target while preserving sufficient target function. Mutations affecting membrane proteins or porins can restrict antibiotic entry, whereas changes in regulatory genes may increase the expression of efflux pumps that remove antimicrobial compounds from the cell. Other mutations can modify metabolic pathways, cellular stress responses, or target-protection systems, thereby increasing bacterial survival during treatment.
Once a favourable mutation becomes established, clonal multiplication can increase its frequency within the population. Successive mutations may then accumulate, producing progressively reduced susceptibility or resistance to several antimicrobial classes. Chromosomal adaptation therefore provides a continuous evolutionary route through which bacterial populations can acquire stable resistance phenotypes without obtaining resistance genes from another organism.
Mobilization of resistance genes by plasmids, transposons, and integrons
The mobility of bacterial genetic material is a major factor facilitating the rapid dissemination of antimicrobial-resistance determinants. Plasmids are extrachromosomal DNA molecules capable of independent replication, and some carry genes that confer resistance to one or several antimicrobial classes. Transferable plasmids can move between compatible bacterial cells, particularly through conjugation, allowing resistance determinants to spread across strains and, in some circumstances, across bacterial species. A single plasmid may carry multiple resistance genes, creating the potential for multidrug-resistant phenotypes following one genetic acquisition event.
Transposons further enhance genetic mobility by enabling DNA segments to relocate between different genetic locations. A resistance gene carried on a transposon can move from the chromosome to a plasmid or between plasmids, thereby increasing its opportunities for transmission. Integrons, although not themselves autonomous mobile elements, are specialized genetic platforms capable of capturing and expressing gene cassettes. Their importance lies in their capacity to assemble multiple resistance determinants within a single genetic region.
When integrons are embedded within plasmids or transposons, the captured genes can gain access to highly mobile genetic vehicles. The combined activity of these elements creates a flexible genetic network through which resistance determinants can be acquired, rearranged, accumulated, and disseminated. This mobility substantially accelerates the spread of resistance within bacterial communities and contributes to the emergence of organisms carrying multiple antimicrobial-resistance traits.
References
Arora D.R (2004). Quality assurance in microbiology. Indian J Med Microbiol, 22:81-86.
Ashutosh Kar (2008). Pharmaceutical Microbiology, 1st edition. New Age International Publishers: New Delhi, India.
Axelsen P.H (2002). Essentials of antimicrobial pharmacology. Humana Press, Totowa, New Jersey, USA. Al-Jasser A.M (2006). Extended – Spectrum Beta – Lactamases (ESBLs): A Global Problem. Kuwait Medical Journal, 38(3):171-185.
Bisht R., Katiyar A., Singh R and Mittal P (2009). Antibiotic Resistance – A Global Issue of Concern. Asian Journal of Pharmaceutical and Clinical Research, 2 (2):34-39.
Block S.S (2001). Disinfection, sterilization and preservation. 5th edition. Lippincott Williams & Wilkins, Philadelphia and London.
Cars O and Nordberg P (2005). Antibiotic resistance: The faceless threat. International Journal of Risk & Safety in Medicine, 17 (3/4): 103-110.
Ejikeugwu Chika, Iroha Ifeanyichukwu, Adikwu Michael and Esimone Charles (2013). Susceptibility and Detection of Extended Spectrum β-Lactamase Enzymes from Otitis Media Pathogens. American Journal of Infectious Diseases. 9(1):24-29.
Finch R.G, Greenwood D, Norrby R and Whitley R (2002). Antibiotic and chemotherapy, 8th edition. Churchill Livingstone, London and Edinburg.
Joslyn, L. J. (2000). Sterilization by Heat. In S. S. Block (Ed.), Disinfection, Sterilization, and Preservation (5th ed., pp. 695-728). Philadelphia, USA: Lippincott Williams and Wilkins.
Lai P.K and Roy J (2004). Antimicrobial and chemopreventive properties of herbs and spices. Curr. Med. Chem, 11 (11): 1451–1460.
Livermore D.M (2004). The need for new antibiotics. Clinical Microbiology & Infection, 4(10): 1-9.
Mascaretti O.A (2003). Bacteria versus antibacterial agents: An integrated approach. Washington: ASM Press.
Nally J.D (Ed.) (2007). Good manufacturing practices for pharmaceuticals. Sixth edition. Informa Healthcare USA, Inc, New York.
Discover more from Microbiology Class
Subscribe to get the latest posts sent to your email.
